Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein

Occupational and Environmental Medicine

Volumn 67, Issue 4, 2010, Pages 233-236

  Cristaudo, Alfonso ^a   Foddis, Rudy ^a   Bonotti, Alessandra ^a   Simonini, Silvia ^a   Vivaldi, Agnese ^a   Guglielmi, Giovanni ^a   Bruno, Rossella ^a   Landi, Debora ^a   Gemignani, Federica ^a   Landi, Stefano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; MESOTHELIN; MICRORNA;

3' UNTRANSLATED REGION; ADULT; ALLELE; ARTICLE; BINDING SITE; CONTROLLED STUDY; EPITHELIUM TUMOR; GENE SEQUENCE; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN EXPERIMENT; MALE; MALIGNANT MESOTHELIOMA; MESOTHELIN GENE; NORMAL HUMAN; OCCUPATIONAL EXPOSURE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

ASBESTOS; ASBESTOSIS; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; MICRORNAS; MIDDLE AGED; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; PLEURAL NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; QUESTIONNAIRES; TUMOR MARKERS, BIOLOGICAL;

EID: 77950549089     PISSN: 13510711     EISSN: 14707926     Source Type: Journal    
DOI: 10.1136/oem.2009.049205     Document Type: Article

References (30)

1. Martino D, Pass HI. Integration of multimodality approaches in the management of malignant pleural mesothelioma [Review]. Clin Lung Cancer 2004;5:290e8.
2. Peto J, De Carli A, La Vecchia C, et al. The European mesothelioma epidemic. BrJ Cancer 1999;79:666e72.
3. Zellos L, Christiani DC. Epidemiology, biologic behaviour, and natural history of mesothelioma [Review]. Thorac Surg Clin 2004;14:469e77, viii.
4. Anon. Asbestos, asbestosis and cancer: the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health 1997;23:311e16.
5. Bocchetta M, Di Resta I, Powers A, et al. Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. Proc Natl Acad Sci USA 2000;97:10214e19.
6. Cutrone R, Lednicky J, Dunn G, et al. Some oral poliovirus vaccines were contaminated with infectious SV40 after 1961. Cancer Res 2005;65:10273e9.
7. Kroczynska B, Cutrone R, Bocchetta M, et al. Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci USA 2006;103:14128e33.
8. Cristaudo A, Foddis R, Vivaldi A, et al. SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study. Cancer Res 2005;65:3049e52.
9. Robinson C, van Bruggen I, Segal A, et al. A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent. Cancer Res 2006;66:10786e94.
10. Pietruska JR, Kane AB. SV40 oncoproteins enhance asbestos induced DNA double-strand breaks and abrogate senescence in murine mesothelial cells. Cancer Res 2007;67:3637e45.
11. Carbone M, Emri S, Dogan AU, et al. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer 2007;7:147e54.
12. Weiner SJ, Neragi-Miandoab S. Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors. J Carcinog 2008;7:3.
13. Neri M, Ugolini D, Dianzani I, et al. Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases [Review]. Mutat Res 2008;659:126e36.
14. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612e16.
15. Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;173:1155e60.
16. Di Serio F, Fontana A, Loizzi M, et al. Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results. Clin Chem Lab Med 2007;45:634e8.
17. Grigori u BD, Scherpereel A, Devos P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007;13:2928e35.
18. Cristaudo A, Foddis R, Vivaldi A, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007;13:5076e81.
19. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 1992;50:373e81.
20. Frierson HF Jr, Moskaluk CA, Powell SM, et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol 2003;34:605e9.
21. Ordoézn NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003;27:1418e28.
22. Pass H, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in Mesothelioma serum and pleural effusions. Ann Thorac Surg 2008;85:265e72.
23. Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with Mesothelioma and ovarian cancer. Clin Cancer Res 2006;12:447e53.
24. Park EK, Sandrini A, Yates DH, et al. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am J Respir Crit Care Med 2008;178:832e7.
25. Li M, Bharadwaj U, Zhang R, et al. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther 2008;7:286e96.
26. Griffiths-Jones S, Grocock RJ, van Dongen S, et al. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acid Res 2006;34:D140e4.
27. John B, Enright AJ, Aravin A, et al. Human microRNA targets. PLoS Biol 2004; 2:e363.
28. Lewis BP, Shih IH, Jones-Rhoades MW, et al. Prediction of mammalian microRNA targets. Cell 2003;115:787e98.
29. SPSS/PC Statistical Package for the Social Science + update for 10.1. Chicago, Illinois: SPSS Inc, 2000.
30. Landi D, Gemignani F, Naccarat i A, et al. Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis 2008;29:579e84.